bioTheranostics, part of the worldwide bioMérieux group, develops molecular diagnostic tests that include supporting the selection of individualized oncology therapies through improved cancer classification and better breast cancer prognosis and recurrence risk stratification. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA
Innovations in cancer diagnostics
Better understanding of the biology underlying patient tumors
bioTheranostics provides molecular diagnostic tests that improve the classification of cancer, and support physicians in determining a more specific breast cancer prognosis or individual risk of recurrence for patients.
All tests are real time, RT-PCR based assays that are compatible with readily available, formalin-fixed paraffin embedded (FFPE) needle core biopsies, excisional biopsies, and/or surgical samples.
Based on 0 Reviews
Add Review